Orasis Pharmaceuticals, an ophthalmic pharmaceutical company delivering solutions to reshape vision possibilities, has announced the availability of Starter Packs of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% to broaden access for patients seeking a flexible option to manage their presbyopia and allow greater first-hand experience for eye care professionals (ECPs). The availability of Qlosi Starter Packs marks the next phase of Qlosi's successful commercial e

Pupil size reduction remained consistent through day 8. More eyes improved from day 1 to day 8. These results suggest neuroadaptation with Qlosi. Qlosi demonstrated consistent pupil size reduction and increasing rates of near visual acuity in patients with presbyopia over 8 days, according to a study. Read more.

Orasis Pharmaceuticals announced that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel, corrective prescription eye...

When Johnson & Johnson learned of the groundbreaking work from Orasis Pharmaceuticals , an emerging ophthalmic pharmaceuticals company,...

In our pursuit of novelty, we sometimes forget that significant treatment breakthroughs have been made thanks to the reformulation or...

Today, Orasis Pharmaceuticals announced that the U.S. Food and Drug Adminstration (FDA) has accepted its New Drug Application (NDA) for...